

<b>AWARD/CONTRACT</b>		1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700)		RATING		PAGE OF PAGES 1 11	
2. CONTRACT (Proc. Inst. Ident.) NO. W81XWH-12-1-0235		3. EFFECTIVE DATE 15 Jul 2012		4. REQUISITION/PURCHASE REQUEST/PROJECT NO. W91ZSQ2105N616			
5. ISSUED BY US ARMY MEDICAL RESEARCH ACQUISITION ACT DIRECTOR 820 CHANDLER STREET FORT DETRICK MD 21702-5014		CODE W81XWH		6. ADMINISTERED BY (If other than Item 5) US ARMY MEDICAL RESEARCH ACQUISITION ACT ATTN: DOUGLAS MEDCALF DOUGLAS.MEDCALF@AMEDD.ARMY.MIL FORT DETRICK MD 21702		CODE W81XWH	
7. NAME AND ADDRESS OF CONTRACTOR (No., street, city, county, state and zip code) NORTHERN CALIFORNIA INSTITUTE FOR RESEAR 4150 CLEMENT ST 151 NC SAN FRANCISCO CA 94121-1545				8. DELIVERY [ ] FOB ORIGIN [X] OTHER (See below)			
				9. DISCOUNT FOR PROMPT PAYMENT Net 30 Days			
				10. SUBMIT INVOICES 1 (4 copies unless otherwise specified) TO THE ADDRESS SHOWN IN:		ITEM	
CODE 0W774		FACILITY CODE		11. SHIP TO/MARK FOR USA MED RESEARCH MAT CMD 1077 PATCHEL STREET BLDG 1077 FORT DETRICK MD 21702		CODE W91ZSQ	
				12. PAYMENT WILL BE MADE BY DEFENSE FINANCE AND ACCOUNTING SERVICE DFAS ROME 325 BROOKS ROAD CUSTOMER SVC:1-800-553-0527 ROME NY 13441-4527		CODE HQ0302	
13. AUTHORITY FOR USING OTHER THAN FULL AND OPEN COMPETITION: [ ] 10 U.S.C. 2304(c)( ) [ ] 41 U.S.C. 253(c)( )				14. ACCOUNTING AND APPROPRIATION DATA <b>See Schedule</b>			
15A. ITEM NO.	15B. SUPPLIES/ SERVICES		15C. QUANTITY	15D. UNIT	15E. UNIT PRICE	15F. AMOUNT	
<b>SEE SCHEDULE</b>							
<b>15G. TOTAL AMOUNT OF CONTRACT</b>						<b>\$296,400.00</b>	
16. TABLE OF CONTENTS							
(X)	SEC.	DESCRIPTION	PAGE(S)	(X)	SEC.	DESCRIPTION	PAGE(S)
<b>PART I - THE SCHEDULE</b>				<b>PART II - CONTRACT CLAUSES</b>			
X	A	SOLICITATION/ CONTRACT FORM	1		I	CONTRACT CLAUSES	
	B	SUPPLIES OR SERVICES AND PRICES/ COSTS		<b>PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS</b>			
	C	DESCRIPTION/ SPECS./ WORK STATEMENT			J	LIST OF ATTACHMENTS	
	D	PACKAGING AND MARKING		<b>PART IV - REPRESENTATIONS AND INSTRUCTIONS</b>			
	E	INSPECTION AND ACCEPTANCE			K	REPRESENTATIONS, CERTIFICATIONS AND OTHER STATEMENTS OF OFFERORS	
	F	DELIVERIES OR PERFORMANCE			L	INSTRS., CONDS., AND NOTICES TO OFFERORS	
	G	CONTRACT ADMINISTRATION DATA			M	EVALUATION FACTORS FOR AWARD	
	H	SPECIAL CONTRACT REQUIREMENTS					
<b>CONTRACTING OFFICER WILL COMPLETE ITEM 17 OR 18 AS APPLICABLE</b>							
17. [ ] CONTRACTOR'S NEGOTIATED AGREEMENT Contractor is required to sign this document and return copies to issuing office.) Contractor agrees to furnish and deliver all items or perform all the services set forth or otherwise identified above and on any continuation sheets for the consideration stated herein. The rights and obligations of the parties to this contract shall be subject to and governed by the following documents: (a) this award/contract, (b) the solicitation, if any, and (c) such provisions, representations, certifications, and specifications, as are attached or incorporated by reference herein. (Attachments are listed herein.)				18. [X] AWARD (Contractor is not required to sign this document.) Your offer on Solicitation Number _____ REF: W81XWH-11-PRCRP-DA including the additions or changes made by you which additions or changes are set forth in full above, is hereby accepted as to the items listed above and on any continuation sheets. This award consummates the contract which consists of the following documents: (a) the Government's solicitation and your offer, and (b) this award/contract. No further contractual document is necessary.			
19A. NAME AND TITLE OF SIGNER (Type or print)				20A. NAME OF CONTRACTING OFFICER WENDY A. BAKER / CONTRACTING OFFICER TEL: 301-619-2034 EMAIL: wendy.a.baker@us.army.mil			
19B. NAME OF CONTRACTOR		19C. DATE SIGNED		20B. UNITED STATES OF AMERICA  BY  (Signature of Contracting Officer)		20C. DATE SIGNED 12-Jun-2012	

## Section 00010 - Solicitation Contract Form

ITEM NO	SUPPLIES/SERVICES	QUANTITY	UNIT	UNIT PRICE	AMOUNT
0001	CA110338 Discovery Award COST Period of Performance: 15 July 2012 - 14 July 2014 FOB: Destination MILSTRIP: W91ZSQ2105N616 PURCHASE REQUEST NUMBER: W91ZSQ2105N616				\$296,400.00
				ESTIMATED COST	\$296,400.00
	ACRN AA CIN: W91ZSQ2105N6160001				\$296,400.00

PI NAME & PROPOSAL TITLE

Current PI Name: Daniel Bikle  
 Proposal Title: The Tumor Suppressor Actions of the Vitamin D Receptor in Skin

## DELIVERY INFORMATION

CLIN	DELIVERY DATE	QUANTITY	SHIP TO ADDRESS	UIC
0001	POP 15-JUL-2012 TO 14-JUL-2014	N/A	USA MED RESEARCH MAT CMD 1077 PATCHEL STREET BLDG 1077 FORT DETRICK MD 21702 FOB: Destination	W91ZSQ

## Section 00800 - Special Contract Requirements

## ACCOUNTING AND APPROPRIATION DATA

AA: 971013018310748119335000009X04150P1FE1MW91ZSQ2105N616FE1MP1018064  
AMOUNT: \$296,400.00  
CIN W91ZSQ2105N6160001: \$296,400.00

## CLAUSES INCORPORATED BY FULL TEXT

**TERMS AND CONDITIONS**  
**U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (USAMRMC)**  
**U.S. ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY (USAMRAA)**  
**Effective October 1, 2011**

## TERMS AND CONDITIONS INCORPORATED BY REFERENCE (APRIL 2012)

The recipient shall comply with the terms and conditions below that are applicable to its type of organization:

a. **For Educational and Non-Profit Organizations:** This award incorporates by reference, with the same force and effect as if they were included in full text, the Research Terms and Conditions dated June 2011 (<http://www.nsf.gov/awards/managing/rtc.jsp>) and the USAMRAA Agency Specific Requirements dated October 1, 2011 (<https://www.usamraa.army.mil>).

b. **For Commercial (For-Profit) Organizations:** This award incorporates by reference, with the same force and effect as if they were included in full text, the USAMRAA General Terms and Conditions for Assistance Awards with For-Profit Organizations dated April 1, 2012 (<https://www.usamraa.army.mil>).

Any apparent inconsistency between Federal statutes and regulations and the terms and conditions contained in this award shall be referred to the USAMRAA Contract/Grants Specialist for guidance.

## AWARD SPECIFIC TERMS AND CONDITIONS

This award is made under the authority of 31 U.S.C. 6304 and 10 U.S.C. 2358. The recipient's revised Statement of Work (SOW) dated 30 May 2012 and the revised budget dated 29 May 2012 for the application submitted in response to the Fiscal Year 2011 Department of Defense (DOD) Peer Reviewed Cancer Research Program Discovery Award Announcement (Funding Opportunity Number: W81XWH-11-PRCRP-DA), which closed 27 October 2011 are incorporated herein by reference. The Catalog of Federal Domestic Assistance Number relative to this award is CFDA 12.420.

## ACCEPTANCE OF AWARD

The recipient is not required to countersign this award. In case of disagreement, the recipient shall notify the USAMRAA Grants Officer and not assess the award any costs until such disagreement(s) is resolved.

ADMINISTRATIVE AND COST PRINCIPLES

The following Administrative and Cost Principles, as applicable, effective the earlier of (i) the start date of this award or (ii) the date on which the recipient incurs costs to be assessed against the award, are incorporated as part of this award by reference:

- a. CFR, Title 2, Part 220, "Cost Principles for Educational Institutions (OMB Circular A-21)."
- b. CFR, Title 2, Part 225, "Cost Principles for State, Local, and Indian Tribal Governments (OMB Circular A-87)."
- c. OMB Circular A-102, "Grants and Cooperative Agreements with State and Local Governments."
- d. CFR, Title 2, Part 215, "Uniform Administrative Requirements for Grants and Agreements with Institutions of Higher Education, Hospitals, and Other Non-profit Organizations (OMB Circular A-110)."
- e. CFR, Title 2, Part 230, "Cost Principles for Non-profit Organizations (OMB Circular A-122)." [For those nonprofit organizations specifically excluded from the provisions of OMB Circular A-122, Subpart 31.2 of the Federal Acquisition Regulations (FAR 48 CFR Subpart 31.2) shall apply].
- f. OMB Circular A-133, "Audits of States, Local Governments, and Non-Profit Organizations."
- g. Federal Acquisition Regulation, Part 31.2, for Commercial Organizations and those nonprofit organizations specifically excluded from the provisions of OMB Circular A-122.
- h. Department of Defense Grant and Agreement Regulations 3210.6-R.

These publications may be obtained from:

Office of Management and Budget  
EOP Publications Office  
New Executive Office Building  
725 17<sup>th</sup> Street, NW, Room 2200  
Washington, DC 20503  
Telephone: (202) 395-7332  
Website: <http://www.whitehouse.gov/omb/>

## **RECIPIENT RESPONSIBILITY**

In addition to the responsibilities of the recipient as defined in the award or incorporated by reference herein:

- a. The recipient will bear primary responsibility for the conduct of the research and will exercise sound judgment within the limits of the award's terms and conditions.
- b. The Principal Investigator(s) (PI) specified in the award document will be continuously responsible for the conduct of the research project and will be closely involved with the research effort. The PI, operating within the policies of the recipient, is in the best position to determine the means by which the research may be conducted most effectively.
- c. The recipient shall request the USAMRAA Grants Officer's prior approval to change the PI or any key personnel, for the PI or any key personnel to be absent from the project during any continuous period of 3 months or more, or for the PI or any key personnel to reduce time devoted to the project by 25 percent or more from the level that was approved at the time of award.

## **AWARD MODIFICATION**

The only method by which this award may be modified is by a formal, written modification signed by the USAMRAA Grants Officer. No other communications, whether oral or in writing, are valid to change the terms and conditions of this award. See the USAMRAA Agency Specific Requirements for changes requiring USAMRAA Grants Officer's prior approval.

### **MAXIMUM OBLIGATION**

The maximum obligation of the Government for support of this award will not exceed the amount specified in the award, as modified. Awards will not be modified to provide additional funds for such purposes as reimbursement for unrecovered indirect costs resulting from the establishment of final negotiated rates or for increases in salaries, fringe benefits, and other costs.

### **SUPPORTING INFORMATION**

Information such as subawards, consultant agreements, vendor quotes, and personnel work agreements may be required in order to support proposed costs or to determine the employment status of personnel. The Government's receipt of this information does not constitute approval or acceptance of any term or condition included therein.

### **FINANCIAL INSTABILITY, INSOLVENCY, BANKRUPTCY OR RECEIVERSHIP**

a. The recipient shall immediately notify the USAMRAA Grants Officer of the occurrence of the following events: (1) the recipient's financial instability that would negatively impact performance of this award; (2) the recipient's or recipient's parent's filing of a voluntary case seeking liquidation or reorganization under the Bankruptcy Act; (3) the recipient's consent to the institution of an involuntary case under the Bankruptcy Act against the organization or organization's parent; (4) the filing of any similar proceeding for or against the recipient or recipient's parent, or its consent to, the dissolution, winding-up or readjustment of the recipient's debts, appointment of a receiver, conservator, trustee, or other officer with similar powers over the organization, under any other applicable state or federal law; or (5) the recipient's insolvency due to its inability to pay its debts generally as they become due.

b. Such notification shall be in writing and shall: (1) specifically set out the details of the occurrence of an event referenced in paragraph a; (2) provide the facts surrounding that event; and (3) provide the impact such event will have on the project being funded by this award.

c. Upon the occurrence of any of the five events described in the first paragraph, the Government reserves the right to conduct a review of this award to determine the recipient's compliance with the required elements of the award (including such items as cost share, progress towards technical project objectives, and submission of required reports). If the USAMRAA Grants Officer's review determines that there are significant deficiencies or concerns with the recipient's performance under the award, the Government reserves the right to impose additional requirements, as needed, including (1) change the payment method; (2) institute payment controls, and (3) require additional reporting requirements.

d. Failure of the recipient to comply with this term may be considered a material failure by the recipient to comply with the terms of this award and may result in termination.

### **PROHIBITION OF USE OF LABORATORY ANIMALS**

#### **\*\* PROHIBITION – READ FURTHER FOR DETAILS \*\***

Notwithstanding any other terms and conditions contained in this award or incorporated by reference herein, the recipient is expressly forbidden to use or subcontract for the use of laboratory animals in any manner whatsoever without the express written approval of the USAMRMC, Animal Care and Use Review Office (ACURO). Written authorization to begin research under the applicable protocol(s) proposed for this award will be issued in the form of an approval letter from the USAMRMC ACURO to the recipient. Furthermore, modifications to

already approved protocols require approval by ACURO prior to implementation. For each fiscal year, the recipient shall maintain, and upon request from ACURO, submit animal usage information.

Non-compliance with any of these terms and conditions may result in withholding of funds and/or the termination of the award.

## **PROHIBITION OF USE OF HUMAN SUBJECTS**

### **\*\* PROHIBITION – READ FURTHER FOR DETAILS \*\***

Research under this award involving the use of human subjects, to include the use of human anatomical substances or identifiable private information, shall not begin until the USAMRMC's Office of Research Protections (ORP) provides authorization that the research may proceed. Written approval to begin research will be issued from the USAMRMC ORP, under separate notification to the recipient. Written approval from the USAMRMC ORP is also required for any subrecipient that will use funds from this award to conduct research involving human subjects.

Research involving human subjects shall be conducted in accordance with the protocol submitted to and approved by the USAMRMC ORP. Complete study records shall be maintained for each human research study and shall be made available for review by representatives of the USAMRMC. Research records shall be stored in a confidential manner so as to protect the confidentiality of subject information.

The recipient is required to adhere to the following reporting requirements:

Submission of major modifications to the protocol, continuing review documentation, and the final report are required as outlined in the USAMRMC ORP approval memorandum.

Unanticipated problems involving risks to subjects or others, subject deaths related to participation in the research, clinical holds (voluntary or involuntary), and suspension or termination of this research by the IRB, the institution, the Sponsor, or regulatory agencies, shall be promptly reported to the USAMRMC ORP.

The knowledge of any pending compliance inspection/visits by the FDA, ORP, or other government agency concerning this clinical investigation or research, the issuance of Inspection Reports, FDA Form 483, warning letters or actions taken by any Regulatory Agencies including legal or medical actions, and any instances of serious or continuing noncompliance with regulatory requirements that relate to this clinical investigation or research, shall be reported immediately to the USAMRMC ORP.

Non-compliance with these terms and conditions may result in withholding of funds and/or the termination of the award.

## **PROHIBITION OF USE OF HUMAN CADAVERS**

### **\*\* PROHIBITION – READ FURTHER FOR DETAILS \*\***

Research under this award using human cadavers for testing military equipment or military protective gear shall not begin until the USAMRMC's ORP approves the protocol. Written approval to begin research or subcontract/subgrant for the use of human cadavers under the applicable protocol proposed for this award will be issued from the USAMRMC ORP under separate notification to the recipient.

Non-compliance with these terms and conditions may result in withholding of funds and/or the termination of the award.

## **PATENTS AND INVENTIONS REPORTING REQUIREMENTS**

a. iEdison and annual reporting. The recipient shall electronically file Invention Disclosures and Patent Applications using the Interagency Edison (iEdison) system through the National Institutes of Health (<https://s->

[edison.info.nih.gov/iEdison](http://edison.info.nih.gov/iEdison)) within the times specified for reporting. In addition, inventions made during the year shall also be reported annually (within 30 days of the anniversary date of the award) on a DD Form 882, "Report of Inventions and Subcontracts." The report shall be sent electronically to [USAMRAA.RED@amedd.army.mil](mailto:USAMRAA.RED@amedd.army.mil). If there are no inventions during the year, no annual DD Form 882 is required. The DD Form 882 can be accessed at <https://www.usamraa.army.mil>.

b. Closeout report. A final DD Form 882 is required. The form shall be submitted electronically to [USAMRAACloseout@amedd.army.mil](mailto:USAMRAACloseout@amedd.army.mil) within 90 days of end of the term of award and shall list all inventions made during the term of the award, or state "none", as applicable. The award will NOT be closed until all reporting requirements have been met.

## FINANCIAL REPORTING REQUIREMENTS

The recipient shall use the Standard Form (SF) 425, "Federal Financial Report," for reporting individual awards. Quarterly and final reports are required for those awards receiving advance payments. Annual and final reports are required for those awards receiving cost reimbursement payments.

The Federal Financial Reporting period end dates fall on the end of the calendar quarter for quarterly reports (3/31, 6/30, 9/30, 12/31), end of the calendar year for annual reports (12/31), and the end date of the term of award for the final report. Reports are due 30 days after the reporting period end date for quarterly and annual reports and 90 days after the end date of the term of the award for the final report.

### Submission Instructions:

a. Access the SF425 form and instructions through the web site <https://usamraa.army.mil>. Complete the form on this site and select the "Submit form" button. An email will be automatically generated to submit to the address [USAMRAASF425@amedd.army.mil](mailto:USAMRAASF425@amedd.army.mil). Before sending the email, change the subject line to read the award number assigned by USAMRAA, which is W81XWH-12-1-0235.

b. A separate email must be submitted for each award. DO NOT include reports for multiple awards in the same email. All SF425s shall be submitted electronically to [USAMRAASF425@amedd.army.mil](mailto:USAMRAASF425@amedd.army.mil) utilizing the procedure outlined above.

## TECHNICAL REPORTING REQUIREMENTS

### a. Annual and Final Technical Reports

Annual and final technical reports are required. Submission of annual and final technical reports, in electronic format (PDF or Word file only), shall be submitted to <https://ers.amedd.army.mil>. Problems accessing this site should be brought to the attention of the USAMRMC Help Desk at 301-619-2049.

Annual reports shall provide a complete summary of the research accomplishments to date with respect to the approved SOW. Journal articles can be substituted for detailed descriptions of specific aspects of the research, but the original articles shall be attached to the report as an appendix and appropriately referenced in the text. The importance of the report to decisions relating to continued support of the research can not be over-emphasized. An annual report shall be submitted within 30 calendar days of the anniversary date of the award for the preceding 12 month period. If the award period of performance is extended by the USAMRAA Grants Officer, an annual report is still required to be submitted within 30 days of the anniversary date of the award.

A final report summarizing the entire research effort, citing data in the annual reports and appended publications, shall be submitted within 90 days of the end of the term of award. The final report shall provide a complete reporting of the research findings. Journal publications can be substituted for detailed descriptions of specific aspects of the research, but an original copy of each publication shall be attached as an appendix and

appropriately referenced in the text. The final report shall include a bibliography of all publications and meeting abstracts and a list of personnel receiving pay (do not include salaries/stipends) from the research effort.

b. Format Requirements

Format requirements are provided at

[https://mrmc.amedd.army.mil/index.cfm?pageid=researcher\\_resources.technical\\_reporting](https://mrmc.amedd.army.mil/index.cfm?pageid=researcher_resources.technical_reporting).

Although there is no page limitation for the reports, each report shall be of sufficient length to provide a thorough description of the accomplishments with respect to the approved SOW. All reports shall have the following elements, in this order:

**FRONT COVER:** The Accession Document (AD) Number should remain blank.

**STANDARD FORM (SF) 298 "Report Documentation Page:"** The abstract in Block 14 shall state the purpose, scope, and major findings, and be an up-to-date report of the progress in terms of results and significance. Subject terms are keywords that may have been assigned to the abstract or are keywords that may be significant to the research. The number of pages shall include all pages that have printed data (including the front cover, SF298, table of contents, and all appendices). Count pages carefully to ensure legibility and that there are no missing pages, as this delays processing of reports. Page numbers shall be typed.

**TABLE OF CONTENTS:** The text of the report shall include all sections addressed in the table of contents, to include:

**INTRODUCTION:** Narrative that briefly (one paragraph) describes the subject, purpose, and scope of the research.

**BODY:** This section of the report shall describe the research accomplishments associated with each task outlined in the approved SOW. Data presentation shall be comprehensive in providing a complete record of the research findings for the period of the report. Provide data explaining the relationship of the most recent findings with that of previously reported findings. Appended publications and/or presentations may be substituted for detailed descriptions of methodology but shall be referenced in the body of the report. If applicable, for each task outlined in the SOW, reference appended publications and/or presentations for details of result findings and tables and/or figures. The report shall include negative as well as positive findings. Include problems in accomplishing any of the tasks. Statistical tests of significance shall be applied to all data whenever possible. Figures and graphs referenced in the text may be embedded in the text or appended. Figures and graphs can also be referenced in the text and appended to a publication. Recommended changes or future work to better address the research topic may also be included. **However, changes to the original SOW shall be approved by the USAMRAA Grants Officer through an award modification prior to initiating any changes.**

**KEY RESEARCH ACCOMPLISHMENTS:** Bulleted list of key research accomplishments emanating from this research.

**REPORTABLE OUTCOMES:** Provide a list of reportable outcomes that have resulted from this research, to include:

- manuscripts, abstracts, presentations;
- patents and licenses applied for and/or issued;
- degrees obtained that are supported by this award;
- development of cell lines, tissue, or serum repositories;
- informatics such as databases and animal models, etc.;
- funding applied for based on work supported by this award;
- employment or research opportunities applied for and/or received based on experience/training supported by this award.



**CONCLUSION:** Summarize the results to include the importance and/or implications of the completed research and, when necessary, recommend changes on future work to better address the problem. A "so what section" which evaluates the knowledge as a scientific or medical product shall also be included.

**REFERENCES:** List all references pertinent to the report using a standard journal format (i.e., format used in Science, Military Medicine, etc.).

**APPENDICES:** Attach all appendices that contain information that supplements, clarifies, or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, surveys, etc.

**SUPPORTING DATA:** All figures and/or tables shall include legends and be clearly marked with figure/table numbers.

Pages shall be consecutively numbered throughout the report. **DO NOT RENUMBER PAGES IN THE APPENDICES.**

Mark all pages of the report which contain proprietary or unpublished data that should be protected by the U.S. Government. **REPORTS NOT PROPERLY MARKED FOR LIMITATION WILL BE DISTRIBUTED AS APPROVED FOR PUBLIC RELEASE.** It is the responsibility of the PI to advise the USAMRMC when restricted limitation assigned to a document can be downgraded to Approved for Public Release. **DO NOT USE THE WORD "CONFIDENTIAL" WHEN MARKING DOCUMENTS.**

## **MANUSCRIPTS/REPRINTS**

Copies of manuscripts or subsequent reprints resulting from the research shall be submitted to the GOR at [cdmrp.reporting@amedd.army.mil](mailto:cdmrp.reporting@amedd.army.mil).

## **DELINQUENT REPORTS**

If the recipient is delinquent on reporting requirements for other USAMRAA-sponsored awards, payments on this award may be withheld until acceptable delinquent reports have been submitted.

## **INVOICING FOR ADVANCE PAYMENTS WITH FULL FUNDING (JANUARY 2012)**

a. Payments. Advance payments will be made to the recipient upon receipt of an invoice submitted through Wide Area Work Flow (WAWF) in accordance with the Contract Line Item Number (CLIN) structure set forth in this award. It is anticipated that Defense Finance and Accounting Service (DFAS) will disburse funds within 30 days of receipt of a proper invoice.

b. **A copy of the most recently submitted Federal Financial Report (SF 425) shall be attached in WAWF and submitted with each invoice for all invoice submissions subsequent to the initial invoice submission.**

c. Electronic Funds Transfer (EFT). All payments will be made by EFT to the recipient's financial institution account listed in the Central Contractor Registry (CCR) (located at <https://www.bpn.gov/ccr>). Failure to update CCR will result in nonpayment.

d. If the recipient fails to perform or if the WAWF invoice submission does not have the most recent SF425 attached, the invoice will be rejected.

e. Interest Bearing Account. Unless exempted by applicable Treasury-State agreements in accordance with the Cash Management Improvement Act (CMIA) (31 U.S.C. 3335), the recipient shall deposit all advance

payments into an interest bearing account. Interest over the amount of \$250 per year shall be remitted annually to the U.S. Department of Health and Human Services, Payment Management System, P.O. Box 6021, Rockville, Maryland 20852. A copy of the transmittal letter stating the amount of interest remitted shall be sent electronically to [USAMRAA.RED@amedd.army.mil](mailto:USAMRAA.RED@amedd.army.mil).

f. Invoicing Schedule for Advances

Year One \$148,200

<u>Amount</u>	<u>Invoice Submission Date (on or about)</u>	<u>CLIN</u>
\$37,050	15 July 2012	(CLIN 0001)
\$37,050	15 October 2012	(CLIN 0001)
\$37,050	15 January 2013	(CLIN 0001)
\$37,050	15 April 2013	(CLIN 0001)

Year Two \$148,200

<u>Amount</u>	<u>Invoice Submission Date (on or about)</u>	<u>CLIN</u>
\$37,050	15 July 2013	(CLIN 0001)
\$37,050	15 October 2013	(CLIN 0001)
\$37,050	15 January 2014	(CLIN 0001)
\$37,050	15 April 2014	(CLIN 0001)

# **ELECTRONIC INVOICING INSTRUCTIONS (JANUARY 2012)**

**Wide Area Work Flow (WAWF) is the required method to electronically process recipient request for payment.** WAWF allows DOD recipients to submit and track invoices electronically.

Recipients shall (i) register to use WAWF at <https://wawf.eb.mil> and (ii) ensure an electronic business point of contact (POC) is designated in the Central Contractor Registration site at <http://www.ccr.gov> within ten (10) calendar days after award of this Assistance Agreement.

Questions concerning specific payments should be directed to the Defense Finance and Accounting Service (DFAS) Rome at 1-800-553-0527. You can also access payment and receipt information using the DFAS web site at <http://www.dfas.mil/dfas/contractorsvendors.html>. The award number or invoice number will be required to inquire about the status of your payment.

**The following codes and information are required to initiate the invoice and assure successful flow of WAWF documents.**

TYPE OF DOCUMENT: Grant and Cooperative Agreement Voucher

CAGE CODE: **0W774**

ISSUE BY DODAAC: **W81XWH**

ADMIN BY DODAAC: **W81XWH**

INSPECT BY DODAAC: **W81XWH**

ACCEPT BY DODAAC: **W81XWH**

SHIP TO DODAAC: **W81XWH**

LOCAL PROCESSING OFFICE DODDAC: **Not Applicable**

PAYMENT OFFICE FISCAL STATION CODE: **HQ0302**

EMAIL POINTS OF CONTACT LISTING:

INSPECTOR: **USAMRAA.RED@amedd.army.mil**

ACCEPTOR: **USAMRAA.RED@amedd.army.mil**

RECEIVING OFFICE POC: **USAMRAA.RED@amedd.army.mil**

CONTRACT ADMINISTRATOR:

CONTRACTING OFFICER:

ADDITIONAL CONTACT: lucinda.keeney@amedd.army.mil

For more information contact Cindy Keeney at 301-619-3325

#### **AWARD CLOSE OUT**

a. The following documents shall be submitted within 90 calendar days of the end of the term of the award:

(1) Final SF425, "Federal Financial Report" (form available on web site <https://www.usamraa.army.mil>)

(2) Final Technical Report

(3) Final DD Form 882, "Report of Inventions and Subcontracts" (form available on web site <https://www.usamraa.army.mil>)

(4) Cumulative listing of only the nonexpendable personal property acquired with award funds for which title has not been vested to the recipient, if applicable. (This may be submitted on institution letterhead.)

(5) "Volunteer Registry Data Sheet," USAMRDC Form 60-R, if applicable. (Form available on the USAMRMC ORP web site <https://www.usamraa.army.mil/pages/pdf/60r.pdf>.) The PI shall complete a form for each subject enrolled in this study and forward in accordance with ORP requirements.

b. In the event a final audit has not been performed prior to the closeout of the award, the sponsoring agency retains the right to recover an appropriate amount after fully considering the recommendations on disallowed costs resulting from the final audit.

c. The recipient shall promptly refund any unspent balances of funds the DOD Component has advanced or paid that is not authorized to be retained by the recipient. **Make check payable to the U.S. Treasury and mail to:**

USAMRAA  
Attn: MCMR-AAA-S  
Award No. W81XWH-12-1-0235  
820 Chandler Street  
Fort Detrick, Maryland 21702-5014



**Application Number:** 1I01BX003814-01A1

**Principal Investigator(s):**

DANIEL David BIKLE, MD

**Project Title:** Vitamin D and Calcium signaling in epidermal stem cell maintenance, activation, and function

Mrs. Yu, Rebecca  
VA Grants Manager, SFVAMC  
4150 Clement Street  
Mail Code: 151  
San Francisco, CA 941211545

**Budget Period:** 01/01/2018 – 12/31/2018

**Project Period:** 01/01/2018 – 12/31/2021

We are pleased to inform you that funding in the amount of \$200,000 (see "Proposed Award Data" in Section I) is being awarded to support the above named project. Funds will be provided by fiscal year according to the award calculation and the budget start date. The funding amounts cited in this Notice of Award may not match the allocations provided to your medical center because funds are provided to VA sites by fiscal year. The VA fiscal year starts on October 1st and ends on September 30th each year. Minor changes to the budget will not be reflected here but can be found in the "Pink Sheet" generated from the VA RAFT program. Contact the VA Research Office at your medical center to obtain a copy of your "Pink Sheet" which will provide you with fiscal year funding amounts and will incorporate changes to the budget.

Please refer to Section III for Terms and Conditions of the award.

If you have questions about this award, please contact the individual(s) referenced in Section II below.

---

**SECTION I – PROPOSED AWARD DATA – 1I01BX003814-01A1**

---

SUMMARY OF PROPOSED TOTALS FOR ALL YEARS	
YR	AWARD
1	\$200,000
2	\$150,000
3	\$150,000
4	\$150,000

Recommended future year total cost support is subject to the availability of funds and satisfactory progress of the project.

---

**SECTION II – CONTACT INFORMATION – 1I01BX003814-01A1**

---

The Program Officer (PO) named below is responsible for the scientific, programmatic and technical aspects of this project.

---

**SECTION III – TERMS AND CONDITIONS – 1I01BX003814-01A1**

---

This award is based on the application submitted to and approved by VA-ORD and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. Award recipients must adhere to VA research policies including VA requirements for progress reports (RPPRs); final reports; research publications; public access to data; intellectual property; and clinical trial registration and reporting required by [clinicaltrials.gov](http://clinicaltrials.gov).
- b. All awards are dependent upon the availability of funds.
- c. Awards should be carried out according to the plan presented in the approved application. Any significant changes in project duration, budget, aims, methods, site(s) or PI must be approved by Biomedical Laboratory Research & Development. Project modifications may be requested using the ORD Project Modification Form located on the Office of Research & Development website at <http://www.research.va.gov/resources/policies/default.cfm>.



NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH

**Grant Number:** 1R21DE025357-01A1  
**FAIN:** R21DE025357

**Principal Investigator(s):**

Yuko Oda, PHD

**Project Title:** The role of Med1 in dental stem cell fate

Murphy, Tiffany  
Grants Specialist  
4150 Clement Street  
151NC  
San Francisco, CA 941211545

**Award e-mailed to:** cgawards@ncire.org

**Period Of Performance:**

**Budget Period:** 09/27/2016 – 08/31/2017

**Project Period:** 09/27/2016 – 08/31/2018

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$229,950 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to NORTHERN CALIFORNIA INSTITUTE/RES/EDU in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Dental & Craniofacial Research of the National Institutes of Health under Award Number R21DE025357. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Gabriel Hidalgo  
Grants Management Officer  
NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH

Additional information follows

---

**SECTION I – AWARD DATA – 1R21DE025357-01A1****Award Calculation (U.S. Dollars)**

Federal Direct Costs	\$150,000
Federal F&A Costs	\$79,950
Approved Budget	\$229,950
Total Amount of Federal Funds Obligated (Federal Share)	\$229,950
<b>TOTAL FEDERAL AWARD AMOUNT</b>	<b>\$229,950</b>

<b>AMOUNT OF THIS ACTION (FEDERAL SHARE)</b>	<b>\$229,950</b>
--	------------------

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$229,950	\$229,950
2	\$191,625	\$191,625

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**Fiscal Information:**

**CFDA Name:** Oral Diseases and Disorders Research  
**CFDA Number:** 93.121  
**EIN:** 1943084159A1  
**Document Number:** RDE025357A  
**PMS Account Type:** P (Subaccount)  
**Fiscal Year:** 2016

IC	CAN	2016	2017
DE	8472268	\$229,950	\$191,625

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**NIH Administrative Data:**

**PCC:** NV1 / **OC:** 414A / **Released:** HIDALGOG 09/27/2016  
**Award Processed:** 09/27/2016 07:01:26 PM

---

**SECTION II – PAYMENT/HOTLINE INFORMATION – 1R21DE025357-01A1**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

---

**SECTION III – TERMS AND CONDITIONS – 1R21DE025357-01A1**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 75.
- National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)



**Research and Development (R&D):** All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R21DE025357. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

**Treatment of Program Income:**  
Additional Costs

---

#### **SECTION IV – DE Special Terms and Conditions – 1R21DE025357-01A1**

**RESTRICTION:** This award is being issued without current other support for *Key Personnel*. Therefore, the grantee/an authorized organizational representative must submit by email the other support for this investigator within 30 days of the issue date and before any funds are drawn down from this award. The grants specialist and email address are listed at the bottom of this award notice.

This award is issued in accordance with, and is subject to, the conditions set forth in PA13-303 "NIH Exploratory/Developmental Research Grant Program -- Parent R21", which are hereby incorporated by reference as special terms and conditions of this award. This RFA/PA may be accessed at: <http://grants.nih.gov/grants/guide/pa-files/PA-13-303.html>.

This is a Modular Grant Award without direct cost categorical breakdowns issued in accordance with the guidelines published in the NIH Grants Policy Statement, October/November 2015, see <http://grants.nih.gov/grants/policy/policy.htm#gps>. Recipients are required to allocate and account for costs related to this award by category within their institutional accounting system in accordance with applicable cost principles.

This award includes funds for twelve months of support. The competing budget period is awarded for less than 12 months. Continuation awards will cycle on September 1st. NIDCR is taking this action to redistribute start dates more evenly throughout the year. Allowable pre-award costs may be charged to this award, in accordance with the conditions outlined

None of the funds in this award shall be used to pay the salary of an individual at a rate in excess of the applicable salary cap. Therefore, this award and/or future years are adjusted accordingly, if applicable. Current salary cap levels can be found at the following URL: <http://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-045.html>.

## STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

**Grants Management Specialist:** April Harrison  
**Email:** harrisona@mail.nih.gov **Phone:** 301-594-4836 **Fax:** 301-480-3562

**Program Official:** Nadya L. Lumelsky  
**Email:** nadyal@nidcr.nih.gov **Phone:** 301-594-7703 **Fax:** (301) 480-8318

## SPREADSHEET SUMMARY

**GRANT NUMBER:** 1R21DE025357-01A1

**INSTITUTION:** NORTHERN CALIFORNIA INSTITUTE/RES/EDU

Budget	Year 1	Year 2
TOTAL FEDERAL DC	\$150,000	\$125,000
TOTAL FEDERAL F&A	\$79,950	\$66,625
TOTAL COST	\$229,950	\$191,625

Facilities and Administrative Costs	Year 1	Year 2
F&A Cost Rate 1	53.3%	53.3%
F&A Cost Base 1	\$150,000	\$125,000
F&A Costs 1	\$79,950	\$66,625



**RESEARCH**

Department of Health and Human Services

National Institutes of Health

NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

Notice of Award

**Issue Date:** 09/22/2014



**Grant Number:** 5R01AR050023-10 REVISED

**FAIN:** R01AR050023

**Principal Investigator(s):**

DANIEL David BIKLE, MD

**Project Title:** Vitamin D Receptor Coactivators in Keratinocytes

Mr. Canete, Douglas  
NORTHERN CALIFORNIA INSTITUTE RES & EDU  
4150 Clement Street (151 NC)  
San Francisco, CA 941211545

**Award e-mailed to:** cgawards@ncire.org

**Budget Period:** 06/01/2014 – 05/31/2015

**Project Period:** 07/01/2003 – 05/31/2015

Dear Business Official:

The National Institutes of Health hereby revises this award (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to NORTHERN CALIFORNIA INSTITUTE/RES/EDU in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Arthritis And Musculoskeletal And Skin Diseases of the National Institutes of Health under Award Number R01AR050023. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Andrew Jones  
Grants Management Officer  
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

Additional information follows

---

**SECTION I – AWARD DATA – 5R01AR050023-10 REVISED**

---

**Award Calculation (U.S. Dollars)**

Federal Direct Costs	\$212,800
Federal F&A Costs	\$102,570
Approved Budget	\$315,370
Federal Share	\$315,370
<b>TOTAL FEDERAL AWARD AMOUNT</b>	<b>\$315,370</b>

**AMOUNT OF THIS ACTION (FEDERAL SHARE)** \$0

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
10	\$315,370	\$315,370

**Fiscal Information:**

**CFDA Number:** 93.846  
**EIN:** 1943084159A1  
**Document Number:** RAR050023B

**PMS Account Type:** G (Pooled)  
**Fiscal Year:** 2014

IC	CAN	2014
OD	8010090	\$83,000
AR	8472466	\$232,370

**NIH Administrative Data:**

**PCC:** 4 A / **OC:** 414E / **Released:** JONESAN 09/22/2014  
**Award Processed:** 05/08/2014 01:52:21 PM

---

**SECTION II – PAYMENT/HOTLINE INFORMATION – 5R01AR050023-10 REVISED**

---

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

---

**SECTION III – TERMS AND CONDITIONS – 5R01AR050023-10 REVISED**

---

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01AR050023. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

This award is not subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award represents the final year of the competitive segment for this grant. See the NIH Grants Policy Statement Section 8.6 Closeout for complete closeout requirements at: <http://grants.nih.gov/grants/policy/policy.htm#gps>.

A final Federal Financial Report (FFR) (SF 425) must be submitted through the eRA Commons (Commons) within 90 days of the expiration date; see the NIH Grants Policy Statement Section 8.6.1 Financial Reports, <http://grants.nih.gov/grants/policy/policy.htm#gps>, for additional information on this submission requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no discrepancies between the final FFR expenditure data and the Payment Management System's (PMS) cash transaction data.

A Final Invention Statement and Certification form (HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted within 90 days of the expiration date. The HHS 568 form may be downloaded at: <http://grants.nih.gov/grants/forms.htm>.

Unless an application for competitive renewal is submitted, a final progress report must also be submitted within 90 days of the expiration date. Instructions for preparing a Final Progress Report are at: <http://grants.nih.gov/grants/funding/finalprogressreport.pdf>. Any other specific requirements set forth in the terms and conditions of the award must also be addressed in the final progress report. Institute/Centers may accept the progress report contained in competitive renewal (type 2) in lieu of a separate final progress report. Contact the awarding IC for IC-specific policy regarding acceptance of a progress report contained in a competitive renewal application in lieu of a separate final progress report.

NIH **strongly encourages** electronic submission of the final progress report and the final invention statement through the Closeout feature in the Commons, but will accept an email or hard copy submission as indicated below.

Email: The final progress report and final invention statement may be e-mailed as PDF attachments to the NIH Central Closeout Center at: [NIHCloseoutCenter@mail.nih.gov](mailto:NIHCloseoutCenter@mail.nih.gov).

Hard copy: Paper submissions of the final progress report and the final invention statement may be faxed to the NIH Division of Central Grants Processing at 301-480-2304, or mailed to:

NIH Division of Central Grants Processing, OER  
6705 Rockledge Drive  
Suite 5016, Room 5109  
MSC 7986  
Bethesda, MD 20892-7986 (for regular or U.S. Postal Service Express mail)  
Bethesda, MD 20817 (for other courier/express mail delivery only)

NOTE: If this is the final year of a competitive segment due to the transfer of the grant to another institution, then a Final Progress Report is not required. However, a final FFR is required and should be submitted electronically as noted above. If not already submitted, the Final Invention Statement is required and should be sent directly to the assigned Grants Management Specialist.

This award is funded by the following list of institutes. Any papers published under the auspices of this award must cite the funding support of all institutes.

Office Of The Director, National Institutes Of Health (OD) National Institute Of Arthritis And Musculoskeletal And Skin Diseases (NIAMS)
---

**Treatment of Program Income:**  
Additional Costs

---

#### **SECTION IV – AR Special Terms and Conditions – 5R01AR050023-10 REVISED**

**REVISION:**

This award is revised to rescind the Non-Compliant Publications Restriction in accordance with the Grantee's revised MYNCBI Table dated 09/20/14.

**ALL PREVIOUS TERMS AND CONDITIONS REMAIN IN EFFECT**

**COFUNDING:** This award includes funding from National Institute of Arthritis and Musculoskeletal Diseases and the Office of Dietary Supplements (ODS). Any papers published under the auspices of this award must cite the funding support of all institutes.

**NON-COMPETING FUNDING LEVEL**

In accordance with current NIAMS FY 2014 policy following the enactment of the Continuing Appropriations Act, 2014 ([H. R. 2775/Public Law 113-46](#)), this non-competing award has been made at a level below that committed for FY2014 in the previous Notice of Award.

**STAFF CONTACTS**

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

**Grants Management Specialist:** Sheila Simmons  
**Email:** simmonss@mail.nih.gov **Phone:** 301-594-9812 **Fax:** 301-480-5450

**Program Official:** Carl Baker  
**Email:** bakerc@mail.nih.gov **Phone:** 301-594-5017 **Fax:** 301-480-4543

**SPREADSHEET SUMMARY**

**GRANT NUMBER:** 5R01AR050023-10 REVISED

**INSTITUTION:** NORTHERN CALIFORNIA INSTITUTE/RES/EDU

Facilities and Administrative Costs	Year 10
F&A Cost Rate 1	48.2%
F&A Cost Base 1	\$212,800
F&A Costs 1	\$102,570